Membranous nephropathy: Quo vadis?  by Cattran, Daniel C.
Kidney International, Vol. 61 (2002), pp. 349–350
EDITORIAL
Membranous nephropathy: Quo vadis?
Idiopathic membranous nephropathy remains the most glomerulosclerosis, that do predict a worse outcome. Un-
common cause of the nephrotic syndrome in adults in the fortunately, these factors are all qualitative and not suf-
world [1]. Because of its frequency, it remains the second ficiently precise for the physician when he or she sits
or third most common cause of end-stage renal disease across the desk from an asymptomatic young woman with
within the primary glomerulonephritis group, despite its proteinuria who not only wants to be completely better
unusual natural history in which many patients have a spon- but also does not want to risk any adverse effects. We
taneous and complete recovery [2]. The debate over its and others have suggested that time must be added to
management has raged since the early 1970s and reached the prognostic mix to improve prediction. Our algorithm,
epidemic proportions in the 1980s following contrary re- which uses only the presenting creatinine level, the quan-
ports on the effectiveness of corticosteroid therapy [3, 4]. tity of proteinuria, and change in renal function over the
An editorial at that time suggested that who to treat and initial 6 months of observation, will substantially improve
at what stage were as relevant as what to use [5]. the ability to separate those individuals with a poor out-
The debate continues today for several reasons. One come from those with a good prognosis [7]. A patient,
relates to the marked variability of its natural history. for example, with 8 g per day or more proteinuria that
The rule of thirds (about the one thing that medical stu- persists for 6 months has an increased likelihood of de-
dents seem to remember about the disease), still seems veloping chronic renal insufficiency from 33% at presen-
to apply with up to one-third of patients spontaneously tation to over 80% at the end of the observation period.
remitting, one-third remaining proteinuric but with sta- We subsequently validated the overall accuracy of pre-
ble renal function, and one-third progressing to renal dicting outcome on a similar group of idiopathic mem-
failure over a period of 5 to 10 years. This outcome has branous nephrology patients from Finland and Italy [8].
not changed much over the past 3 decades as indicated This would indicate that the first part of this question has
by a recent publication reporting a 30% spontaneous been answered, that is, we can now semi-quantitatively
complete remission rate at 5 years and 25% proceeding predict outcome within 6 to 12 months of presentation
to end-stage renal disease by the end of 8 years [6]. in most patients.
This is despite our advances in surveillance, lower blood The second part of this controversial area is whether
pressure targets, and better antihypertensive agents, we lose our ability to effectively treat patients by waiting.
some with the additional capacity to drive down protein- This is at least partially answered by the article by Torres
uria. Thus, it is clear that if we have an effective and et al [9] in this issue of Kidney International. Although
safe treatment, we should use it, since an end-stage renal retrospective in nature, with all its attendant problems
disease rate of 25% at 8 years is unacceptable. of case mix and different time frames, none of those in
The second area of controversy is composed of two the treatment group received any therapy until their
parts. First, can we accurately predict those patients who creatinine levels were1.5 mg/dL or creatinine clearance
will progress to end-stage renal disease? And, second, was60 mL/minute measured on at least three occasions.
can we accomplish it early enough that the kidney will As well, the time to reach this point was, on average, 14
still retain the ability to improve with treatment, but late months after their biopsy. All patients received the same
enough to avoid therapy in those patients who will remit therapy, oral prednisone beginning at 0.5 mg/kg/day ta-
spontaneously? The concern of many is that if we wait pered slowly over 6 months plus chlorambucil 0.15 mg/
for the clearest sign of progression, that is, deterioriation kg/day for 14 weeks. Despite the elevated creatinine
in renal function, the opportunity for effective treatment level and time delay, the treatment was associated with
will be blunted or prevented. Currently, there are a num- a decreasing serum creatinine level in 60% of the treated
ber of factors, including advanced age, male sex, severity patients and was associated with decreasing proteinuria.
of initial proteinuria and renal insufficiency, plus histo- Only 30% went on to develop chronic renal insufficiency
logic changes, such as tubular interstitial damage and compared to 75% of patients treated conservatively. This
report would suggest that we can safely wait and observe
the patient before beginning treatment and still effect aKey words: glomerulonephritis, end-stage renal disease, proteinuria,
creatinine levels. change in its natural history.
This paper by Torres et al [9] also lends some support 2002 by the International Society of Nephrology
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